PSORIASIS

This study tested whether people with stable psoriasis could safely reduce their dose of IL17 or IL23 inhibitor drugs without causing flare-ups. 244 adults with well-controlled psoriasis were randomly assigned to either dose reduction or standard care. The goal was to see if lowe…

This study followed 240 adults in Taiwan with moderate to severe plaque psoriasis to see how long risankizumab stays effective compared to other biologic drugs. Participants received their prescribed treatment and were monitored for about 2 years. The goal was to measure skin cle…

This study tested an experimental drug called BI 655130 in 59 adults with palmoplantar pustulosis (PPP), a skin condition causing painful pus-filled blisters on the palms and soles. The goal was to see if the drug could reduce the severity of the rash and was safe compared to a p…

This study tested a gel called SGX302 (synthetic hypericin) combined with visible light to treat mild-to-moderate psoriasis. 15 adults with plaque psoriasis applied the gel to their skin and received light therapy over 18 weeks. The goal was to see if the treatment could clear or…

This study looked at 781 adults with moderate to severe plaque psoriasis and metabolic syndrome (a cluster of conditions like high blood pressure and obesity). Participants either received the drug Secukinumab alone or combined with a lifestyle intervention (diet and exercise adv…

This study tested a new oral drug, SAR441566, in 221 adults with moderate to severe plaque psoriasis. Participants received either the drug or a placebo for 12 weeks. The main goal was to see if the drug could reduce psoriasis severity by at least 75% compared to starting point.

This pilot study tested higher-than-standard doses of risankizumab in 20 adults with moderate-to-severe plaque psoriasis. The goal was to see if higher doses could better clear the skin and reduce certain immune cells (resident memory T cells) that may cause psoriasis to return. …

This study looked at whether adding metformin, a common diabetes drug, to cyclosporine works better than cyclosporine alone for treating psoriasis. Psoriasis is a chronic skin condition that causes red, scaly patches. The study involved 32 adults with moderate to severe psoriasis…

This study looked at over 2,300 adults with moderate to severe plaque psoriasis or psoriatic arthritis who were prescribed Skyrizi (risankizumab) by their doctor. Researchers wanted to see how safe the drug is and how well it controls symptoms over 52 weeks. Participants received…

This study looked at whether people with moderate-to-severe plaque psoriasis who had clear skin after 20 weeks of guselkumab treatment could keep their skin clear by getting the medicine every 16 weeks instead of the usual schedule. About 880 adults took part. The goal was to see…

This study looked at how safe and effective OTEZLA is for people with psoriasis (skin plaques) or psoriatic arthritis when used in normal doctor visits. Over 1,000 adults who had not gotten enough relief from creams or other skin treatments took part. Researchers tracked side eff…

This study looked at the long-term safety and effects of the drug apremilast in children aged 6 to 17 with moderate to severe plaque psoriasis. Participants who completed a previous year-long study could continue taking apremilast for up to 208 weeks (about 4 years), followed by …

This study tested whether a new drug, CMAB015, works as well as the approved drug secukinumab for people with moderate to severe plaque psoriasis. 336 adults received injections of either drug over 48 weeks. The main goal was to see if at least 75% of their skin cleared up after …

This study looked at whether tildrakizumab, a drug already approved for psoriasis, can improve blood flow to the heart in people with moderate-to-severe psoriasis. 36 adults received the drug for 6 months, and researchers measured changes in coronary flow reserve using heart scan…

This study tested a device called Efferon CT that filters the blood to remove extra immune proteins (cytokines) that drive psoriasis. Sixty adults with moderate-to-severe plaque psoriasis received this treatment alongside their usual therapy. The goal was to see if filtering the …

This study tested whether tofacitinib, a drug already approved for other conditions, is safe and helpful for people with Down syndrome who also have immune-related skin problems like eczema, psoriasis, or hair loss. The study included 47 adolescents and adults. Researchers measur…

This study tested whether the drug deucravacitinib can safely and effectively treat moderate-to-severe scalp psoriasis compared to a placebo. About 154 adults with stable plaque psoriasis affecting the scalp took part. The main goal was to see how many achieved clear or almost cl…

This study tested a medicated lotion (IDP-118) in 16 children aged 4 to 16 with moderate to severe plaque psoriasis. Researchers measured how much of the drug entered the blood and whether it affected the body's stress hormone system. The goal was to ensure the lotion is safe for…

This study tested whether drugs that block reverse transcriptase (normally used for HIV) could help treat psoriasis. The idea was that these drugs might reduce inflammation by targeting DNA loops in skin cells. Eight adults with plaque psoriasis took part, and researchers checked…

This study tested whether time-restricted feeding (eating all daily calories between 8 am and 2 pm) can reduce inflammation in men with mild to moderate psoriasis. Participants stayed at the clinic for 5 days, followed the eating schedule, and had blood tests to measure immune ma…

This study tested a special moisturizing cream (RL3020-DP0364) in 40 adults with mild plaque psoriasis, dry skin, and itching. The cream creates a protective film to keep skin hydrated and protect it from irritants. Researchers measured how well it reduced itching over 29 days. T…

This study involved 30 adults with mild-to-moderate psoriasis who had previously used Enstilar foam. Researchers asked participants to try Wynzora cream and then report which treatment they preferred. The goal was to see if people liked Wynzora more, and also to check how well th…

This study tested an experimental drug called BMS-986322 in 109 adults with moderate-to-severe plaque psoriasis. The goal was to see if the drug safely reduces skin symptoms like redness, thickness, and scaling. Participants received either the drug or a placebo for 12 weeks, and…

This study tested a new drug called AX-158 in 31 adults with mild to moderate plaque psoriasis. Participants took either the drug or a placebo for 28 days, then were monitored for 30 more days to check safety. The main goal was to see if the drug is safe and tolerable, with some …

This study looked at whether intermittent fasting (eating only during certain hours) can reduce disease severity and improve quality of life for people with psoriasis and psoriatic arthritis. Sixty overweight adults were randomly assigned to either follow an intermittent fasting …

This study tested an 8-week smartphone-based cognitive behavioral therapy (CBT) program for 30 adults with psoriasis and mild to moderate depression. Participants used a coach-guided app to learn skills to manage their mood and skin condition. The goal was to see if the program w…

This study tested a 12-week online coaching program called "Immune Strength" to see if it could improve mental health in adults with psoriatic arthritis or psoriasis. The program provided weekly access to a wellness professional and focused on sleep, activity, stress, and nutriti…

This study tested a new drug called ASKP1240 in 60 people with moderate to severe plaque psoriasis. The goal was to see if the drug is safe and how it works in the body compared to a placebo. Participants received multiple doses, and researchers measured drug levels, immune syste…

This study tested a light-based device called Lumiton to see if it could improve skin and hair conditions like psoriasis, alopecia areata, and polymorphous light eruption. Eighteen adults used the device at home, and researchers measured changes in disease severity using photos a…

This early-stage study tested an experimental oral drug, SAR441566, in 38 adults with mild to moderate psoriasis. The main goal was to check safety and tolerability over 4 weeks, while also measuring how well it reduced skin symptoms like scaling and redness. Participants were ra…

This study tested a drug called deucravacitinib to see if it improves quality of life for people with plaque psoriasis. 180 adults with moderate-to-severe psoriasis took either the drug or a placebo. The main goal was to see how many achieved clear or almost clear skin and felt t…

This study looked at skin samples from 40 people with psoriasis to understand how certain immune cells (CD4+ T cells) and a protein called S100A7 behave in the disease. Researchers used special staining techniques to measure these substances in the skin. The goal was to learn mor…

This study checked if newer psoriasis medications (IL17/23 inhibitors) can also improve heart health by measuring artery stiffness. Researchers followed 66 adults with moderate-to-severe psoriasis for one year, comparing those on the new drugs to those on standard treatments. The…

This study looked at 52 adults with psoriasis who had been on biologic drugs for at least one year. Researchers used questionnaires to find out which medical and psychological factors, like personality type, affect how satisfied patients feel with their treatment. The goal is to …

This study looked at how psoriasis affects blood flow and nerve sensitivity in the skin. Twenty adults with psoriasis on their back took part. Researchers measured skin blood flow and nerve responses on both psoriasis plaques and healthy skin to understand the link between nerves…

This study looked at whether people with psoriasis have worse gum health and how it affects their quality of life. Researchers compared 226 adults with and without psoriasis through mouth exams and questionnaires. The goal was to understand the link between psoriasis and oral hea…

This study looked at skin samples from 170 people with psoriasis, atopic dermatitis, or healthy skin to understand how a protein called Lyn is involved in inflammation. Researchers measured Lyn levels and activity, along with other inflammatory markers. The goal was to see if a s…

This study looked at fatigue in 33 adults with psoriatic arthritis or psoriasis. Researchers used questionnaires to compare tiredness levels and see if they relate to disease severity or type of treatment. The goal was to better understand fatigue, a common but poorly understood …

This study tested a new questionnaire called DermCLCI-p to see if it accurately measures the long-term life impact of psoriasis. 154 adults with moderate-to-severe psoriasis starting the drug risankizumab filled out the survey. The goal was to check if the tool is reliable and us…

This study followed over 2,300 adults with moderate to severe plaque psoriasis to see how safe and effective the drug secukinumab is in everyday use. Researchers recorded side effects and how well the treatment cleared skin symptoms. The goal was to gather real-world evidence, no…

This study looked at how psoriasis, a skin condition caused by inflammation, might be linked to heart disease and other metabolic problems. Researchers followed 386 adults with psoriasis for up to 4 years, using blood tests, heart scans, and imaging to measure inflammation in blo…

This study involved 37 adults with psoriasis or psoriatic arthritis who were starting or switching treatments. Researchers worked with patients and doctors to create a decision aid—a simple tool to help people discuss their options and make shared choices. The goal was to improve…

This study tested how the psoriasis drug Hemay005 behaves in people with mild or moderate kidney issues versus those with normal kidneys. 26 adults took a single dose, and researchers measured drug levels in the blood. The goal was to help doctors decide the right dose for patien…

This study looked at 100 adults with moderate-to-severe psoriasis to see how two biologic drugs, Secukinumab and Adalimumab, affect bone density. Psoriasis is a chronic inflammatory condition that can raise the risk of weak bones (osteopenia or osteoporosis). Researchers measured…

This study tested whether an artificial intelligence (AI) device could help doctors more accurately diagnose 13 different skin conditions, from rashes to skin cancer. Sixteen doctors (10 general practitioners and 6 dermatologists) reviewed 29 skin images, first giving a diagnosis…

This completed Phase 1 study involved 20 adults with psoriasis to see how Hemay005 tablets affect the way the body processes another drug (midazolam). Researchers also checked for heart rhythm changes and measured inflammation markers. The goal was to gather safety and interactio…